Otsuka reported top-line Phase IIIb results for centanafadine in patients with ADHD and comorbid anxiety, marking another clinical development milestone for its non-stimulant program. The company said the once-daily compound met the primary endpoint at week 8, with improvements on the Adult Investigator Symptom Rating Scale versus placebo. The update keeps centanafadine positioned as an alternative approach for ADHD patients where stimulants may be less suitable or not preferred. The presence of comorbid anxiety also shapes the potential target population and trial design considerations for future registrational studies. Otsuka’s next steps will hinge on how regulators interpret the efficacy profile across symptom domains and whether the data support a clear differentiation versus existing ADHD treatments.